background

Filter By Category

Active Pharma Ingredients
Disease Dictionary

Archives

Posted by -

Active Pharma Ingredients / 14 Sep 2026

BISNAFIDE

Generic Name: BISNAFIDE

ABSTRACT -

Bisnafide is a Small molecule antineoplastic. It is generally described as a DNA-intercalating/topoisomerase-directed antineoplastic candidate.

This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.

DOSAGE -

  • Dosage should be determined only by a qualified healthcare professional.
  • Use only according to the approved label, clinical protocol, or specialist direction.
  • Dose strength, route, frequency, and duration depend on indication, formulation, renal/hepatic status, and concomitant therapy.
  • Do not substitute salt forms, investigational forms, or combination products without formal product review.

SIDE EFFECTS-

Possible side effects and safety concerns include:

  • Headache, dizziness, nausea, fatigue, rash, or gastrointestinal discomfort
  • Laboratory abnormalities may occur depending on mechanism and indication
  • Class-specific organ toxicity should be monitored according to the product label or protocol
  • Serious hypersensitivity reactions are uncommon but possible.

ALLERGIC REACTIONS -

Hypersensitivity to Bisnafide or related compounds/products may occur. Symptoms may include:

  • Immediate urticaria or generalized rash
  • Facial, lip, tongue, or throat swelling
  • Wheezing or breathing difficulty
  • Dizziness, collapse, or anaphylaxis

Important: Patients who develop an allergic reaction to Bisnafide should seek immediate medical attention and inform all future healthcare providers of the allergy.

DRUG INTERACTIONS-

Bisnafide may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:

  • CYP enzyme inhibitors or inducers may alter exposure for many small molecules.
  • Transporter interactions may affect absorption, distribution, or elimination.
  • Additive pharmacodynamic effects may occur with medicines affecting the same pathway.
  • Patients should disclose prescription medicines, over-the-counter medicines, vaccines, herbal products, and supplements.

PREAUTONS–

  • Confirm identity, formulation, strength, route, and intended indication before use.
  • Review allergy history and prior serious adverse reactions.
  • Assess renal/hepatic function and clinically relevant laboratory values when applicable.
  • Pregnancy, lactation, pediatric, and geriatric use should follow label or protocol guidance.

WARNINGS –

  • This document is for structured API information only and is not a prescribing guide.
  • Use only according to approved labeling, clinical-trial protocol, or qualified specialist instruction.
  • Stop use and seek urgent medical care for severe allergic reaction, breathing difficulty, collapse, or serious unexpected symptoms.
  • Keep out of reach of children.

Have any questions? or Need help Contact us – 022 6163 6163 | support@medicus.com

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2026 Copyright. All rights reserved. Powered by . Developed by Hats-Off

Log in with your credentials

Forgot your details?

Feedback